Technology
Health
Biotechnology

Rexahn Pharmaceuticals

$4.96
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.13 (2.69%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell RNN and other stocks, options, ETFs, and crypto commission-free!

About

Rexahn Pharmaceuticals, Inc., also called Rexahn Pharmaceuticals, is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. Read More The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.

Employees
10
Headquarters
Rockville, Maryland
Founded
2001
Market Cap
19.93M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
69.42K
High Today
$4.96
Low Today
$4.78
Open Price
$4.78
Volume
4.28K
52 Week High
$27.36
52 Week Low
$4.71

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Research And Development
Cancer Prevention
Therapy

News

Yahoo FinanceMay 13

Rexahn Pharmaceuticals Reports First Quarter 2019 Financial Results

ROCKVILLE, Md., May 13, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced financial results for the first quarter ended March 31, 2019. First Quarter 2019 and Recent Highlights: Completed enrollment in the Phase 2a clinical trial of RX-3117 in combination with ABRAXANE ® (paclitaxel protein-bound particles for injectable ...

155

Earnings

-$0.93
-$0.63
-$0.34
-$0.04
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.93 per share
Actual
-$0.62 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.